ID30327A - EKSPRESI DAN EKSPOR PROTEIN-PROTEIN ANTI OBESITAS SEBAGAI PROTEIN-PROTEIN FUSI Fc - Google Patents

EKSPRESI DAN EKSPOR PROTEIN-PROTEIN ANTI OBESITAS SEBAGAI PROTEIN-PROTEIN FUSI Fc

Info

Publication number
ID30327A
ID30327A IDW00200101488A ID20011488A ID30327A ID 30327 A ID30327 A ID 30327A ID W00200101488 A IDW00200101488 A ID W00200101488A ID 20011488 A ID20011488 A ID 20011488A ID 30327 A ID30327 A ID 30327A
Authority
ID
Indonesia
Prior art keywords
proteins
fotiin
export
fusion
expression
Prior art date
Application number
IDW00200101488A
Other languages
English (en)
Indonesian (id)
Inventor
Lo Kin Ming
Zhang Jinyang
Stephen Gillies
Original Assignee
Lexigen Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexigen Pharm Corp filed Critical Lexigen Pharm Corp
Publication of ID30327A publication Critical patent/ID30327A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IDW00200101488A 1999-01-07 2000-01-07 EKSPRESI DAN EKSPOR PROTEIN-PROTEIN ANTI OBESITAS SEBAGAI PROTEIN-PROTEIN FUSI Fc ID30327A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11507999P 1999-01-07 1999-01-07

Publications (1)

Publication Number Publication Date
ID30327A true ID30327A (id) 2001-11-22

Family

ID=22359200

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101488A ID30327A (id) 1999-01-07 2000-01-07 EKSPRESI DAN EKSPOR PROTEIN-PROTEIN ANTI OBESITAS SEBAGAI PROTEIN-PROTEIN FUSI Fc

Country Status (16)

Country Link
US (1) US20040053366A1 (no)
EP (1) EP1141013A2 (no)
JP (1) JP2002534962A (no)
KR (1) KR20020007287A (no)
CN (1) CN1341121A (no)
AU (1) AU778939B2 (no)
BR (1) BR0007414A (no)
CA (1) CA2356401A1 (no)
CZ (1) CZ20012406A3 (no)
HU (1) HUP0105090A2 (no)
ID (1) ID30327A (no)
MX (1) MXPA01006922A (no)
NO (1) NO20013371L (no)
SK (1) SK9432001A3 (no)
WO (1) WO2000040615A2 (no)
ZA (1) ZA200105352B (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69824039T2 (de) 1997-12-08 2005-08-18 Lexigen Pharmaceuticals Corp., Lexington Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
WO1999052562A2 (en) * 1998-04-15 1999-10-21 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6617135B1 (en) * 1999-08-09 2003-09-09 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
WO2001058957A2 (en) * 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
MXPA02012734A (es) * 2000-06-29 2003-04-25 Merck Patent Gmbh Mejoramiento de las respuestas inmunes mediadas por la proteina de fusion anticuerpo-citocina, mediante tratamiento combinado con agentes mejoradores de la captacion de inmunocitocina.
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
AU2002233340B2 (en) * 2001-02-19 2008-05-22 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
MXPA03008031A (es) * 2001-03-07 2003-12-04 Merck Patent Gmbh Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida.
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CN100503639C (zh) * 2001-05-03 2009-06-24 默克专利有限公司 重组肿瘤特异性抗体及其应用
WO2003048334A2 (en) * 2001-12-04 2003-06-12 Merck Patent Gmbh Immunocytokines with modulated selectivity
ATE471946T1 (de) * 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
JP4870569B2 (ja) 2003-11-13 2012-02-08 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
JP2008502317A (ja) 2003-12-30 2008-01-31 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Ｉｌ−７融合タンパク質
WO2005063808A1 (en) * 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
AU2005203962C1 (en) 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
AU2005206277B2 (en) * 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
ES2342964T3 (es) * 2004-12-09 2010-07-20 Merck Patent Gmbh Variantes de la interleucina-7 con inmunogenicidad reducida.
EP1838736B1 (en) 2005-01-05 2013-03-06 Biogen Idec MA Inc. Cripto binding molecules
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
EP1909823A2 (en) * 2005-07-29 2008-04-16 Amprotein Corporation Chimeric therapeutic agents
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
EP1801121A1 (en) * 2005-12-23 2007-06-27 CONARIS research institute AG Soluble gp130 molecule variants useful as a medicament
ATE509954T1 (de) 2005-12-30 2011-06-15 Merck Patent Gmbh Anti-cd19-antikörper mit reduzierter immunogenität
ATE555125T1 (de) 2005-12-30 2012-05-15 Merck Patent Gmbh Interleukin-12p40-varianten mit verbesserter stabilität
US7846434B2 (en) * 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
US20080227669A1 (en) * 2007-03-12 2008-09-18 Halliburton Energy Services, Inc. Corrosion-inhibiting additives, treatment fluids, and associated methods
KR20110028457A (ko) 2008-05-21 2011-03-18 뉴로테즈 인코포레이티드 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법
JP2012508242A (ja) 2008-11-04 2012-04-05 ニコラオス テザプシディス 神経原線維のもつれ及びアミロイドβの蓄積に起因する進行性認知機能障害を治療するためのレプチン組成物及び方法
EP2421896A1 (en) 2009-04-22 2012-02-29 Merck Patent GmbH Antibody fusion proteins with modified fcrn binding sites
CA2832581C (en) 2011-04-08 2022-08-23 Yumei Xiong Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3626739A1 (en) 2011-06-24 2020-03-25 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
WO2013113008A1 (en) 2012-01-26 2013-08-01 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
PL2880170T3 (pl) * 2012-08-02 2017-02-28 F.Hoffmann-La Roche Ag SPOSÓB WYTWARZANIA ROZPUSZCZALNEGO FcR JAKO FUZJI Fc Z OBOJĘTNYM REGIONEM Fc IMMUNOGLOBULINY I JEGO ZASTOSOWANIA
KR20150037959A (ko) * 2012-08-02 2015-04-08 에프. 호프만-라 로슈 아게 단량체 및 다량체 분자의 제조 방법 및 이의 용도
CN104736558A (zh) * 2012-09-07 2015-06-24 赛诺菲 用于治疗代谢综合征的融合蛋白
EP3763734A1 (en) * 2013-07-31 2021-01-13 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10913786B2 (en) 2016-03-21 2021-02-09 Children's Medical Center Corporation Compositions and methods for inhibiting Wnt signaling
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US20180009869A1 (en) * 2016-07-08 2018-01-11 AskGene Pharma, Inc. Fusion Protein Comprising Leptin and Methods for Producing and Using the Same
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN111954537A (zh) 2018-04-09 2020-11-17 美国安进公司 生长分化因子15融合蛋白
US11197910B1 (en) * 2020-08-19 2021-12-14 Vitruviae LLC Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
WO1996031526A1 (en) * 1995-04-06 1996-10-10 Amylin Pharmaceuticals, Inc. Anti-obesity agents
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound

Also Published As

Publication number Publication date
JP2002534962A (ja) 2002-10-22
WO2000040615A3 (en) 2000-11-23
NO20013371D0 (no) 2001-07-06
WO2000040615A2 (en) 2000-07-13
EP1141013A2 (en) 2001-10-10
CN1341121A (zh) 2002-03-20
CA2356401A1 (en) 2000-07-13
AU778939B2 (en) 2004-12-23
MXPA01006922A (es) 2002-04-24
BR0007414A (pt) 2001-10-16
CZ20012406A3 (cs) 2002-03-13
KR20020007287A (ko) 2002-01-26
US20040053366A1 (en) 2004-03-18
HUP0105090A2 (hu) 2002-04-29
SK9432001A3 (en) 2003-02-04
AU2602500A (en) 2000-07-24
NO20013371L (no) 2001-09-04
ZA200105352B (en) 2002-06-28

Similar Documents

Publication Publication Date Title
ID30327A (id) EKSPRESI DAN EKSPOR PROTEIN-PROTEIN ANTI OBESITAS SEBAGAI PROTEIN-PROTEIN FUSI Fc
HUP0201474A2 (en) Expression and export of interferon-alpha proteins as fc fusion proteins
ATE247484T1 (de) Von der telomerase abgeleitete antigene peptide
AU2002361642A8 (en) Recombinant antibody fusion proteins and methods for detection of apoptotic cells
ATE198491T1 (de) System zur expression von heterologen antigenen als fusionsproteine
ATE328101T1 (de) Strukturprotein von adeno-assoziiertem virus mit veränderten chromatographischen eigenschaften
ATE462725T1 (de) Expression und export von angiostatin und endostatin als immunofusins
IL158126A0 (en) Peptides and antibodies to muc 1 proteins
IL160512A0 (en) Virus coat protein/receptor chimeras and methods of use
NO991340D0 (no) Stamme-seleksjon av pneumococcale overflateproteiner, beslektede anvendelser
AU2002220460A1 (en) The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits
ATE368225T1 (de) Verwendung von antikörpern gegen spezifische mhc- peptidkomplexe
NO20042173L (no) Fremgangsmate for fremstilling av rekombinant polypeptid
EP1523492A4 (en) FUSION PROTEIN IGG FC / HIV-GP120 / C3D
NO20000575D0 (no) Rekombinant ekspresjon av insulin C-peptid
DE69938579D1 (de) Extrazelluläre Matrixproteine mit modifizierten Aminosäuren
PL373052A1 (en) Platlet glycoprotein ib alpha fusion polypeptides and methods of use thereof
AU2002251999A1 (en) Methods and compositions for the construction and use of fusion libraries using computational protein design methods
ID26730A (id) Induksi protein-protein dan peptida-peptida antibiotik oleh lait/scd14-protein
DE69823225D1 (de) Fusionsproteine, bestehend aus proteinaseinhibitoren
FI953422A0 (fi) Autolysoivia fuusioproteiineja hyväksikäyttävät ilmentämisjärjestelmät ja uusi pelkistävä polypeptidi
AU2486900A (en) Rubredoxin fusion proteins, protein expression system and methods
NO20021763D0 (no) Modifiserte peptider og peptiddomimetics for anvendelse ved immunoterapi
NO992531D0 (no) FremgangsmÕter ved fremstilling av rekombinant protein
AU2002342858A1 (en) Human high-affinity antibody fragments for essential proteins of the hepatitis-c virus